Lenvatinib Versus Sorafenib In First-Line Treatment Of Patients With Unresectable Hepatocellular Carcinoma: A Randomised Phase 3 Non-Inferiority Trial

·2018·DOI

Role in the Field

Abstract

Citations

3,456

Year

2018

PageRank

3.9 / 10

Relative influence (log-scaled)

Lenvatinib Versus Sorafenib In First-Line Treatment Of Patients With Unresectable Hepatocellular Carcinoma: A Randomised Phase 3 Non-Inferiority Trial | Manumap